Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.66 - $30.41
Previous CloseN/A
Volume680.40K
Average Volume (3M)1.47M
Market Cap
$1.90B
Enterprise Value$2.67B
Total Cash (Recent Filing)$2.59M
Total Debt (Recent Filing)$796.42K
Price to Earnings (P/E)―
Beta2.01
Next Earnings
May 08, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding137,317,370
10 Day Avg. Volume1,599,250
30 Day Avg. Volume1,471,229
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)746.50
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit751.83
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$40.60Price Target Upside218.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive Phase 1/2 data with ARO-C3 support confidence in the blockbuster potential of Arrowhead's complement disease franchise.
Regulatory ApprovalNDA filing places plozasiran on-track for potential approval for the treatment of familial chylomicronemia syndrome, which could generate near-term value for shareholders.
Strategic PartnershipsThe collaboration with SRPT has closed, and ARWR will receive $825mm, consisting of $500mm cash and $325mm as an equity investment priced at a 35% premium to 30-day volume weighted average price.
Bears Say
Capital RequirementsARWR continues to see rationale for a CVOT (CAPITAN trial in mixed dyslipidemia) but awaits substantial further capital to initiate the study.
Development RisksRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials.
---
Ownership Overview
4.15% Insiders
16.19% Mutual Funds
22.41% Other Institutional Investors
31.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $13.66 and its highest was $30.41 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $1.90B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 37 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.914.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.44.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 137,317,370 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went down -5.171%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
---
Arrowhead Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.60 (218.68% Upside)
$40.60 (218.68% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 956.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $971.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.45%
12-Months-Change
Fundamentals
Return on Equity
-600.68%
Trailing 12-Months
Asset Growth
61.86%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines that treat intractable diseases by silencing the genes that cause them. The company leverages its proprietary Targeted RNAi Molecule (TRiM) platform to design and develop therapies for the treatment of various conditions, including those affecting the liver, lungs, and tumors. Arrowhead is committed to improving the lives of patients by advancing a robust pipeline of drug candidates across multiple therapeutic areas.
---
ARWR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with major highlights such as the closing of a significant deal with Sarepta Therapeutics, upcoming launches, and strong pipeline advancements in obesity and CNS. However, increased operating expenses and a higher net loss were noted as lowlights, with some uncertainties regarding the timing of the CVOT for plozasiran.Read More>---
ARWR Stock 12 Month Forecast
Average Price Target
$40.60
▲(218.68% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arcturus Therapeutics
―
Moderna
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/40 ratings generated profit
1 Year Average Return
+26.17%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +26.17% per trade.
---